Medidata Launches Industry’s Most Comprehensive Program to Support Clinical Trials Diversity Initiatives
Innovative Program Uses Data and Patient Insights to Help Sponsors and CROs Create Diversity Action Plans
New York – September 19, 2023 Medidata, a Dassault Systèmes company, today announced the launch of the Medidata Diversity Program, the industry’s most comprehensive solution for improving diversity, equity, and inclusion in clinical trials.
The Medidata Diversity Program supports biopharmaceutical and medical device companies and clinical research organizations (CROs) by addressing common systemic and clinical barriers that can hinder a diverse range of individuals from participating in clinical trials. By combining capabilities across Medidata AI and Medidata Patient Cloud portfolios, the program creates a novel and unique approach to achieving diversity throughout the clinical trial process by improving awareness and experiences for patients, streamlining access to trials, enabling decentralization, and supporting data-driven decision-making needed to execute the modern diversity action plans required for regulatory success.
This landmark launch coincides with increasing dialogue among industry leaders and regulators about the need for greater diversity throughout the clinical trial process. Historically, clinical trials have recruited predominantly Caucasian participants, rather than being representative of the patient populations most affected by the disease. These blind spots can lead to a lack of understanding about how treatments may affect different populations and create inequitable access to treatments that complicate data accuracy and the path to future clinical development.
The U.S. Food and Drug Administration (FDA) indicated that achieving greater diversity in clinical trials will be a key focus for regulators to help evaluate new treatments and methods – especially in therapeutic areas that are known to disproportionately impact diverse communities. The FDA’s latest Draft Guidance on Diversity Plans aims to improve enrollment of underrepresented populations in clinical trials by encouraging investigators and sponsors to create a framework to define and meet specific diversity goals.
“Facilitating more diverse participation in clinical trials is a critical and complex challenge, not only for the life sciences industry but for the patients and caregivers participating in the trials,” said Anthony Costello, Chief Executive Officer, Patient Cloud, Medidata. “The Medidata Diversity Program, the most comprehensive solution to date, will help sponsors and CROs move from awareness about a diversity challenge to planning and solving for it as a standard and sustainable part of their clinical development programs.”
The Diversity Program comprises a suite of innovative and industry-leading solutions including Medidata AI Intelligent Trials, myMedidata Registries and eConsent, the Medidata Patient Insights Program, and Medidata’s partnership with Circuit Clinical – a national network of sites focused on diverse patient populations with localized investigators, trained on Medidata decentralized clinical trial technology. Designed to embed diversity into every aspect of the process, this program positions Medidata as a catalyst for cultivating diversity, closing disparities, and achieving true clinical trial success.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
###
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.
Contact:
Medidata PR
Analyst Relations